Instructional Course - Requires Course Pass, Additional Registration Required

Instructional Course

019IC - Immunotherapy for the Urologist: Basic Principles, Adverse Effects & Drug Delivery

Friday, May 18
4:00 PM - 6:00 PM
Location: MCC WEST, 2002

The goal of the course is to provide both a basic and real-world application of immunotherapy for genitourinary oncology. The course is directed towards the urologist with an interest, but no prior experience delivering immunotherapy agents to patients with bladder and kidney cancer (with possible application to prostate cancer in the future). Starting with innovating breakthroughs, new therapies and their side-effects, the course will also cover common side-effects and biomarkers to risk stratify patients. We will plan to discuss real world-challenges in starting an immunotherapy program, from regulatory requirements to coding and billing for systemic therapies.

Learning Objectives:

Joshua Meeks

Assistant Professor of Urology
Northwestern University

Joshua Meeks, MD, PhD is an Assistant Professor of Urology at Northwestern Univeristy. His research laboratory is focused on the molecular pathways involved in the progression of urothelial carcinoma. Dr. Meeks's research has two themes: 1) to investigate the epigenetic mechanisms of gene regulation in bladder cancer and 2) to identify the interaction of the immune response to tumor mutations. Dr. Meeks has a clinical trial study of intravesical immunotherapy for BCG-refractory bladder cancer at Northwestern and is the bladder-site translational medicine chair for the SouthWest Oncology (SWOG) GU Committee. Dr. Meeks specializes in the surgical treatment of non-muscle and muscle-invasive bladder cancer with an emphasis on maintaining urinary and sexual function after bladder removal.


Send Email for Joshua Meeks

Peter C. Black

University of British Columbia

Dr. Peter Black, MD, FACS, FRCSC is a Urologic Oncologist at Vancouver General Hospital, a Research Scientist at the Vancouver Prostate Centre, and Professor in the Department of Urologic Sciences at the University of British Columbia (UBC). He received his undergraduate degree from the UBC and his medical degree from Johannes Gutenberg University in Mainz, Germany. He completed his urologic training at the University of Washington in Seattle and fellowship in Urologic Oncology at M.D. Anderson Cancer Center in Houston, Texas. He has a clinical subspecialty interest in bladder cancer and also a translational research program in urothelial carcinoma. This research focuses on the integration of advanced biomarkers and novel targeted therapies to promote precision oncology and is supported by peer-reviewed grant funding.


Send Email for Peter Black

Terence Friedlander

University of California, San Francisco

I am a clinical and translational oncologist specializing in cancers of the genitourinary tract, specifically bladder and prostate cancers. My research is focused on understanding the basic biology these malignancies and in developing novel therapeutic ways to treat disease. I have investigated advanced prostate and bladder cancer, particularly exploring the predictive value of circulating tumor cells (CTCs) in these malignancies. As a clinical academic oncologist I serve as principal investigator or co-investigator on a number clinical trials in advanced prostate and bladder cancer, including many studies of immunotherapy. These clinical trials allow us to recruit patients for much of our biomarker work. I hope this work will help us to be able to predict which are likely to respond to existing and novel therapies and allow us to tailor our clinical strategy to avoid giving toxic and ineffective therapies, and to select patients most likely to benefit.


Send Email for Terence Friedlander

Neal D. Shore

Carolina Urologic Research Center

Neal D. Shore, MD, FACS
Director, CPI, Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.
Dr. Shore has conducted more than 250 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Society of Urologic Oncology Clinical Trials Consortium, Secretary-Treasurer, and is President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee; he is currently a member of the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE(Academic Editor), Urology Practice, and serves as Editor, Everyday Urology. He has more than 125 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, European Urology,Journal Urology, Urology, BJUI,PCPD, and numerous other high impact scientific journals.
A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6 month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.


Send Email for Neal Shore

Brian Shuch

Yale School of Medicine

I joined the faculty at Yale in August 2013 as a urologic surgeon after completing urology residency at UCLA and an oncology research fellowship at the National Cancer Institute (NCI). I have specific interest in the genetics of urologic cancers and have helped describe the clinical manifestations of several kidney cancer syndromes while at the NCI as well as establish kidney genetic testing guidelines. I served on the Cancer Genome Atlas (TCGA) kidney cancer working groups, the NCI PDQ Cancer Genetics Board, and the NCCN Kidney Cancer Guidelines Panel. My clinical responsibilities focus on kidney cancer and I run the Yale Genitourinary Cancer Genetics clinic and have a clinical protocol for surveillance of the small renal mass. I perform open, laparoscopic, robotic, and percutaneous kidney surgeries and am an active investigator several adjuvant and neoadjuvant protocols. I am active in the SWOG GU Cancer group and the SUO Clinical Trial Consortium. I serve as the Director of the Yale Genitourinary Cancer Biospecimen Repository and run a translational research laboratory. My current translational research involves evaluation of renal tumor heterogeneity, using bioinformatics to guide clinical treatment, the molecular mechanisms associated with sarcomatoid transformation, and predictive markers of response to MET inhibitors in papillary kidney cancer.


Send Email for Brian Shuch

Kelly L. Stratton

Department of Urology, Stephenson Cancer Center, University of Oklahoma

Kelly Stratton MD, is an Assistant Professor of Urologic Oncology and Adjunct Assistant Professor of Medical Oncology at the University of Oklahoma, Stephenson Cancer Center. He serves as the Disease Site Chair for Urologic Cancers and as a member of the Oklahoma TSET Phase I Clinical Trials Program. He completed his urology training at Vanderbilt University Medical Center and fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center. His interests include clinical trial development and the treatment of localized and advanced cancers with immunotherapeutic agents. He also has a focus in prostate cancer imaging, MRI/US Fusion Biopsy, and focal treatment of localized prostate cancer.


Send Email for Kelly Stratton

Robert Svatek

UT Health Science Center


Send Email for Robert Svatek


019IC - Immunotherapy for the Urologist: Basic Principles, Adverse Effects & Drug Delivery


Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Immunotherapy for the Urologist: Basic Principles, Adverse Effects & Drug Delivery